Who
Sarah Gheuens
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Agios Pharmaceuticals; Director, Viridian Therapeutics.
In numbers
- Trades disclosed
- 138
- Buys
- 0
- Sells
- 20
- Bought
- $0
- Sold
- $4.3M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 2 Dec 2021
- Last trade
- 22 Oct 2026
- Last filed
- 23 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Oct 2026filed 23 Oct 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $13K500 at $25.01 | filing |
| 22 Oct 2026filed 23 Oct 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $19K500 at $37.52 | filing |
| 22 Oct 2026filed 23 Oct 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —500 at $0.00 | filing |
| 21 Oct 2026filed 23 Oct 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $37K1,489 at $25.01 | filing |
| 21 Oct 2026filed 23 Oct 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $56K1,489 at $37.53 | filing |
| 21 Oct 2026filed 23 Oct 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,489 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $914K30,000 at $30.48 | filing |
| 4 Aug 2026filed 6 Aug 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $914K30,000 at $30.48 | filing |
| 1 Jul 2026filed 2 Jul 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,341 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,341 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —8,375 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $151K4,007 at $37.56 | filing |
| 1 Jul 2026filed 2 Jul 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,375 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,375 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —8,375 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $151K4,007 at $37.56 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
News
Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sarah Gheuens Sells 500 Shares of Company Stockdailypolitical.com · 23 Oct 2026Agios Pharmaceuticals (NASDAQ:AGIO) Stock: Insider Sarah Gheuens Sells 1,489 Sharesdailypolitical.com · 23 Oct 2026Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sarah Gheuens Sells 1,489 Shares of Stocktickerreport.com · 23 Oct 2026Contrasting Revolution Medicines (NASDAQ:RVMD) and Agios Pharmaceuticals (NASDAQ:AGIO)AGIO · themarketsdaily.com · 22 Oct 2026
3 headlines in the last 90 days name Sarah Gheuens; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.